Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A spinout company from our Department, OxSight, has reported that in a recent UK-wide trial its smart glasses helped sight impaired and blind people to navigate independently, avoid collisions and see in the dark.

The technology was developed in our Department by visual prosthetics researcher Dr Stephen Hicks with support from the Oxford Eye Hospital. Hicks’ team used their understanding of how the brain interprets visual information to develop algorithms that replicate our natural visual interpretation process.

Behind these glasses is ten years of work developing a real-time computer vision algorithm that mimics some of the basic components of human visual perception. The algorithm detects the distance to nearby objects and forms a depth-map which is then enhanced and displayed on the inside of a pair of glasses. It highlights edges and features which make many objects easier to see, especially in low light where many people struggle.
-  Dr Stephen Hicks

The OxSight smart glasses use a unique camera system and computer vision algorithms to detect and highlight objects, separating them from the background in real-time. This allows people with even the lowest amount of sight make better use of their vision in challenging everyday scenarios.

Participants in the trial reported that they were able to describe people standing several meters away and in some cases even recognise their faces and expressions.

OxSight has successfully raised a seed funding round from Oxford angel investor Mr Zhang Jiangong. The company will use the funding to continue to develop the smart glasses. Existing partners include Google, the Royal National Institute of Blind People, the University of Oxford, the NIHR i4i scheme, the Royal Academy of Engineering and Oxford University Innovation. Both Mr Zhang and RTC Innovation, a UK-based technology transfer company have provided valuable support to OxSight over the last 3 years.

Read more from Oxford University Innovation...

Similar stories

Direct evidence of reduced NMDA receptors in people with form of encephalitis

NMDAR-antibody encephalitis is an autoimmune brain condition caused by patient’s own antibodies that bind to NMDA (N-Methyl-D-Aspartate) receptors in the synapses between nerve cells.

Director of MRC Brain Network Dynamics Unit appointed

From 2 January 2023, Professor Peter Magill will lead the Medical Research Council Brain Network Dynamics Unit (MRC BNDU) at the University of Oxford.

Study reveals association between diagnosis of a neuropsychiatric condition and severe outcome from COVID-19 infection, and other severe acute respiratory infections

New research from the University of Oxford has shown an increased risk of severe illness and death from both COVID-19 and other severe respiratory infections, such as influenza and pneumonia, among people with a pre-existing mental health condition.

New study shows clinical symptoms for Alzheimer’s can be predicted in preclinical models

Establishing preclinical models of Alzheimer’s that reflect in-life clinical symptoms of each individual is a critically important goal, yet so far it has not been fully realised. A new collaborative study from the University of Oxford has demonstrated that clinical vulnerability to an abnormally abundant protein in Alzheimer’s brain is in fact reflected in individual patient induced pluripotent stem cell-derived cortical neurons.

Visit from the Sir Jules Thorn Charitable Trust

Earlier this month, we were delighted to welcome the Director of the Sir Jules Thorn Charitable Trust, Richard Benson, and its Chair of Trustees, Liz Charal.